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OBJECTIVE—To create an immunodeﬁcient mouse model that
spontaneously develops hyperglycemia to serve as a diabetic
host for human islets and stem cell–derived -cells in the
absence or presence of a functional human immune system.
RESEARCH DESIGN AND METHODS—We backcrossed the
Ins2
Akita mutation onto the NOD-Rag1
null IL2r
null strain and
determined 1) the spontaneous development of hyperglycemia,
2) the ability of human islets, mouse islets, and dissociated
mouse islet cells to restore euglycemia, 3) the generation of a
human immune system following engraftment of human hema-
topoietic stem cells, and 4) the ability of the humanized mice to
reject human islet allografts.
RESULTS—We conﬁrmed the defects in innate and adaptive
immunity and the spontaneous development of hyperglycemia
conferred by the IL2r
null, Rag1
null, and Ins2
Akita genes in
NOD-Rag1
null IL2r
null Ins2
Akita (NRG-Akita) mice. Mouse and
human islets restored NRG-Akita mice to normoglycemia. Insu-
lin-positive cells in dissociated mouse islets, required to restore
euglycemia in chemically diabetic NOD-scid IL2r
null and spon-
taneously diabetic NRG-Akita mice, were quantiﬁed following
transplantation via the intrapancreatic and subrenal routes.
Engraftment of human hematopoietic stem cells in newborn
NRG-Akita and NRG mice resulted in equivalent human immune
system development in a normoglycemic or chronically hyper-
glycemic environment, with 50% of engrafted NRG-Akita mice
capable of rejecting human islet allografts.
CONCLUSIONS—NRG-Akita mice provide a model system for
validation of the function of human islets and human adult stem
cell, embryonic stem cell, or induced pluripotent stem cell–
derived -cells in the absence or presence of an alloreactive
human immune system. Diabetes 59:2265–2270, 2010
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nvestigators are working to develop functional hu-
man -cells from adult or embryonic stem cells
(ESCs) or from induced pluripotent stem (iPS) cells
(1–4), and human ESC-derived -cells can restore
euglycemia in streptozotocin (STZ) diabetic immunodeﬁ-
cient mice (5). However, STZ can have detrimental effects
on many organs in addition to -cells (6,7), and there is
sometimes recovery of the host -cell function (8,9). In
addition, it will be important to transplant human -cells
in the presence of an allogeneic human immune system.
We have developed an immunodeﬁcient mouse model
of spontaneous hyperglycemia based on NOD-Rag1
null
Prf1
null mice bearing the Ins2
Akita mutation (10). Mice
heterozygous for Ins2
Akita develop spontaneous hypergly-
cemia at 3–6 weeks of age (11,12), and transplantation of
human islets restores euglycemia (10). However, human
immune system engraftment is relatively inefﬁcient in this
model (13). Immunodeﬁcient scid and Rag1
null NOD mice
bearing a mutation in the interleukin (IL)-2 receptor
common  chain (IL2r
null) gene are now available (14,15)
and can be engrafted with functional human immune
systems (14–18).
We now describe the development of the NOD-Rag1
null
IL2r
null Ins2
/Akita (NRG-Akita) strain. These mice de-
velop spontaneous hyperglycemia, and euglycemia can be
restored following transplantation with mouse or human
islets or with dissociated mouse islet cells. A human
immune system develops following engraftment with hu-
man hematopoietic stem cells (HSCs), and in some mice,
this immune system is capable of rejecting human islet
allografts.
RESEARCH DESIGN AND METHODS
NOD-Rag1
null IL2r
null (NRG) (14), NOD-Rag1
null Prf1
null Ins2
Akita (10), and
NOD-scid IL2r
null (NSG) (15) mice have previously been described. To
generate NRG-Akita mice, NOD.Cg-Rag1
tm1Mom Prf1
null Ins2
Akita mice were
crossed with the NOD-Rag1
null IL2r
null strain. Additional crosses ﬁxed the
wild-type Prf1 allele and the IL2r
null mutation to homozygosity while
maintaining the Ins2
Akita mutation in the heterozygous state. Mice were
housed in a speciﬁc pathogen-free facility in microisolator cages (15). All
animal use was in accordance with the guidelines of the IACUCs of the
University of Massachusetts and The Jackson Laboratory.
Antibodies and ﬂow cytometry. The phenotypes of murine cells were
determined using four color analyses (15). Anti-human FoxP3 (eBioscience,
San Diego, CA), anti-human CD123 and BDCA2 (Miltenyi Biotec, Bergisch
Gladbach, Germany), anti-human CD11c (Biolegend, San Diego, CA), and
anti-human CD235a (Coulter Immunotech, Miami, FL) were obtained as
indicated. All other antibodies were purchased from BD Biosciences (San
Jose, CA).
Bone marrow, spleen, and thymus cell suspensions and heparinized blood
were incubated with anti-mouse FcR11b to block Fc binding (14,19). Cells
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diabetes.diabetesjournals.org DIABETES, VOL. 59, SEPTEMBER 2010 2265were prepared for ﬂow cytometry, and at least 50,000 events were acquired on
BD Biosciences LSRII or FACSCalibur instruments (BD Biosciences)
(14,15,20). For rare populations, we acquired at least 500 speciﬁc events. Data
analysis was performed with FlowJo (Tree Star, Ashland, OR) software.
Mouse and human islet transplantation. Handpicked BALB/c islets (21)
were also dissociated into single-cell suspensions (22). Dissociated islet cell
suspensions were treated with Cytoﬁx/Cytoperm (BD Biosciences) for intra-
cellular staining using a biotinylated anti-insulin antibody and developed with
Streptavidin-allophycocyanin (SA-APC). Dissociated preparations contained a
mean  SD of 62  19% (n  10) insulin-positive cells. Islets or dissociated
cells were transplanted intrapancreatically or subrenally into STZ diabetic
NSG mice (150 mg/kg) or unmanipulated diabetic NRG-Akita recipients.
Human islets were obtained from Juvenile Diabetes Research Foundation
Islet Isolation Centers or the National Institutes of Health Integrated Islet
Distribution Program. Human islets (IEQs) (4,000) were transplanted subre-
nally into diabetic NSG or NRG-Akita mice. Nonfasting blood glucose levels
were determined twice weekly. Loss of graft function was determined by two
consecutive blood glucose values 250 mg/dl.
Engraftment of mice with human HSCs. NRG mice or progeny of NRG 
NRG-Akita matings (50% heterozygous for Ins2
Akita) 1–3 days old were
irradiated with 400 cGy and engrafted with umbilical cord blood. HSCs were
provided by the University of Massachusetts Memorial Umbilical Cord Blood
Donation Program under insitutional review board approval (14,20). Mice
were analyzed phenotypically 12–16 weeks later and/or transplanted with
human islet allografts.
Histology. Pancreata and islet transplants were stained with hemotoxlin-
eosin (H-E) and for insulin, glucagon, and human CD45 (16). Unilateral
nephrectomy of the graft-bearing kidney was performed on selected cohorts
to conﬁrm recurrent hyperglycemia. In some cases, islet allograft survival was
inferred with histological study.
Statistical analyses. Most data are presented as means  SD, and ﬂow
cytometry data are presented as means  SEM. Parametric data were
compared by one-way ANOVA with Bonferroni posttests to compare individ-
ual pairwise groupings. Nonparametric data were compared by a Kruskal-
Wallis with Dunns posttest to compare individual pairwise groupings.
Signiﬁcant differences were assumed for P values 	0.05. All statistical
analyses were performed using GraphPad Prism software (version 4.0c;
GraphPad, San Diego, CA).
RESULTS
Phenotype of the hematopoietic system of NRG-Akita
mice. To develop an immunodeﬁcient strain of mice
bearing the Ins2
Akita mutation that will support the devel-
opment of a human immune system following engraftment
with HSC, we generated NRG-Akita mice. Because mice
homozygous for Ins2
Akita develop a rapid hyperglycemia
and die shortly after weaning (10), all studies were per-
formed using mice heterozygous for the Ins2
Akita allele.
Flow cytometry analysis of NRG-Akita splenocytes con-
ﬁrmed the lack of mature T, B, and natural killer (NK) cells
(supplemental Table 1, available in the online appendix
[http://diabetes.diabetesjournals.org/cgi/content/full/db10-
0323/DC1]). Although cells with an NK phenotype (DX5
/
CD122
) were observed, these cells are not mature NK
cells (15). Populations of granulocytes and macrophages
in NRG and NRG-Akita mice were similar (supplemental
Table 1), documenting that NRG-Akita mice are deﬁcient
in adaptive immunity and NK cells.
Spontaneous hyperglycemia in NRG-Akita mice and
reversal by islet transplantation. All male and female
NRG-Akita mice developed hyperglycemia between 3 and
5 weeks of age and remained diabetic, viable, and healthy
in the absence of exogenous insulin (Fig. 1). In contrast,
NRG (Ins2
/) littermates remained euglycemic through-
out their life span.
Normal islet architecture and insulin and glucagon
staining were observed in the pancreata of NRG mice at all
ages (Fig. 1). At 3 weeks of age, the pancreata of
NRG-Akita mice were only slightly disorganized and
strong insulin staining was observed. By 32 weeks of age
in hyperglycemic NRG-Akita mice, islet architecture was
disorganized and condensed. Some insulin-positive cells
were present but scattered throughout the islet. No inﬂam-
matory inﬁltrates were observed.
Subrenal transplantation of 20 mouse islets/g body wt
into hyperglycemic NRG-Akita mice restored normoglyce-
mia (Fig. 2). Islet graft recipients remained normoglycemic
to the end of observation periods or, in selected cases,
reverted to hyperglycemia following removal of the graft-
bearing kidney (data not shown).
Transplantation of 4,000 IEQ human islets into the
subrenal capsular space routinely restored euglycemia in
NRG-Akita mice (Fig. 2). These islets remained functional
throughout the observation periods—in some cases over
300 days. Graft survival was conﬁrmed by histology or by
removal of the graft-bearing kidney and reversion to
hyperglycemia (data not shown).
Restoration of normoglycemia by transplantation of
mouse islets or dissociated islet cells into diabetic
NSG or NRG-Akita mice. Intrapancreatic transplantation
of 20 islets/g body wt into STZ diabetic NSG mice failed to
restore normoglycemia, whereas 40 islets/g body wt re-
stored normoglycemia in two of seven recipients (supple-
mental Fig. 1). Using dissociated islet cells, more than 5 
10
5 insulin-positive -cells was required for restoration of
normoglycemia following subrenal transplantation in dia-
betic NSG mice (supplemental Fig. 1).
In diabetic NRG-Akita mice, intrapancreatic transplan-
tation of 40 mouse islets/g body wt restored normoglyce-
mia in three of four NRG-Akita mice, whereas 20 islets/g
body wt restored normoglycemia in only one of three
NRG-Akita recipients (supplemental Fig. 2). This is in
contrast to restoration of normoglycemia in diabetic NRG-
Akita recipients following subrenal transplantation of 20
mouse islets/g body wt (Fig. 2).
Intrapancreatic transplantation of dissociated mouse
islet cells containing 1–4  10
6 insulin-positive -cells
restored euglycemia in only one of ﬁve diabetic NRG-Akita
recipients (supplemental Fig. 2). Only two of six hypergly-
cemic NRG-Akita mice became euglycemic after subrenal
transplantation with 1–4  10
6 dissociated mouse islet
cells (supplemental Fig. 2). These data document 1) that
dissociated mouse islets can restore normoglycemia in
diabetic NSG and NRG-Akita mice and 2) that fewer
insulin-positive cells are required for restoration of nor-
moglycemia following subrenal compared with intrapan-
creatic transplantation.
Engraftment of human HSCs in NRG-Akita mice. We
have shown that NRG mice engraft with human HSC at
levels similar to those observed in NSG mice (14), but the
effect of chronic hyperglycemia on the development of a
human immune system is unknown.
NRG-Akita and NRG littermates were injected with
human HSCs (14,20). Twelve weeks later, hyperglycemia
was conﬁrmed in NRG-Akita mice (data not shown).
Similar percentages of splenic human CD45
 cells and all
human cell subsets were observed in hyperglycemic NRG-
Akita acompared with euglycemic NRG mice (Table 1).
Comparable levels of human CD45
 and human cell
subsets were also observed in the bone marrow, blood,
and thymus of hyperglycemic NRG-Akita and euglycemic
NRG mice (supplemental Tables 2–4). These data docu-
ment that the human immune systems that develop in
hyperglycemic NRG-Akita mice appear phenotypically
comparable with those developing in normoglycemic NRG
mice.
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engrafted NRG-Akita mice. Eight of nine human islet
recipients of 4,000 IEQ restored normoglycemia (	250
mg/dl) (Fig. 3) in non–HSC-engrafted diabetic NRG-Akita
mice. In contrast, eight of 13 human islet allografts were
rejected in HSC-engrafted NRG-Akita mice (Fig. 3). Insulin
staining in the absence of mononuclear cell inﬁltration
was detected in human islet allografts in non–HSC-en-
grafted NRG-Akita mice (Fig. 3). In the eight HSC-en-
grafted NRG-Akita human islet recipients that reverted to
hyperglycemia, human CD45
 cell inﬁltration into the
graft site and loss of -cells were observed. In the ﬁve
HSC-engrafted NRG-Akita mice that did not revert to
hyperglycemia, insulin-positive cells and human CD45

cell islet inﬁltration were observed (Fig. 3).
DISCUSSION
We have previously described the development of sponta-
neously diabetic NOD-Rag1
null Prf1
null Ins2
Akita mice
(10), but NOD-Rag1
null Prf1
null mice engraft poorly with
human immune systems (23). To address this limitation,
we generated NRG-Akita mice that spontaneously develop
hyperglycemia. Euglycemia can be restored following
transplantation with mouse or human islets or with disso-
ciated mouse islet cells. Even in the presence of a state of
chronic hyperglycemia, a human immune system develops
following engraftment with human HSCs that is capable of
rejecting human islet allografts in some of the transplanted
mice.
Unmanipulated NRG-Akita mice maintain a phenotype
consistent with a severely immunodeﬁcient mouse bearing
IL2r and Ins2
Akita mutated genes. Both male and female
mice develop hyperglycemia between 3 and 5 weeks of
age, and islets progressively lose insulin-positive cells with
age. However, small numbers of insulin-positive cells
remain throughout life, perhaps explaining why adminis-
tration of exogenous insulin is not required for long-term
survival.
We conﬁrmed that transplantation of mouse or human
islets restores euglycemia in diabetic NRG-Akita and NSG
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FIG. 1. Onset of hyperglycemia and islet morphology in male and female NRG-Akita mice. Male (A) and female (C) NRG-Akita and NOD-Rag1
null
IL2r 
null littermate control mice were followed for >200 days with blood glucose monitored at the days of age indicated as described in RESEARCH
DESIGN AND METHODS. Data points shown are of individual animals. Pancreata from male (B) and female (D) NRG-Akita and NOD-Rag1
null IL2r
null
littermate control mice at the indicated ages were stained with H-E and immunohistochemically for insulin and glucagon. Young and older control
NRG (/) mice and young NRG-Akita (/Akita) mice displayed normal architecture and histochemical structure with insulin-positive cells
throughout the islets and a peripheral rim of glucagon-positive cells. Older NRG-Akita mice displayed collapsed islet structure with fewer
insulin-positive -cells and numerous glucagon positive cells scattered throughout the islets. Blood glucose levels of the mice at the time of
recovery of the pancreas are shown at the bottom of each panel. Magniﬁcation 400. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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intrapancreatic implantation than were needed following
subrenal transplantation to restore euglycemia. Our data
also suggest that single-cell suspensions of insulin-produc-
ing cells may be less functional than comparable numbers
contained within an islet structure.
We conﬁrmed that a human immune system develops in
diabetic NRG-Akita mice engrafted with human HSCs, and
this immune system is phenotypically comparable with
that generated in euglycemic NRG mice. However, only
60% of human immune system–engrafted NRG-Akita
mice rejected human islet allografts. In separate studies,
HSC-engrafted NSG mice readily reject human skin allo-
grafts (M.A.B., unpublished observations), but it is known
that skin allografts prompt a more robust alloimmune
response than do islet allografts (24,25). Alternatively, the
human immune system may be impaired as a result of the
hyperglycemic environment—or we may not have allowed
sufﬁcient time for graft rejection.
In summary, we have developed a new model of spon-
taneous hyperglycemia based on immunodeﬁcient NOD
mice bearing mutations in the IL2r gene and the Ins2
Akita
gene. NRG-Akita mice can be engrafted with a human
immune system, providing a recipient environment similar
to that which will be encountered when transplanting
allogeneic -cells in the clinic. These mice provide a novel
model system suitable for validation of the function of
stem cell–derived human -cells in the absence or pres-
ence of an alloreactive human immune system.
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FIG. 2. Transplantation of mouse and human islets into diabetic
NRG-Akita mice. Diabetic NRG-Akita mice were transplanted in the
renal subcapsular space with 4,000 IEQ human islets or with 20 islets/g
body wt mouse islets as described in RESEARCH DESIGN AND METHODS.
Blood glucose levels were determined, and the kidney bearing the islet
transplant and the host pancreas were recovered at the end of the
experiment for histological and immunohistological analyses. A: H-E,
insulin, and glucagon staining of transplanted mouse (left panel) and
human (right panel) islets and host pancreas of the NRG-Akita trans-
plant recipient at the times indicated after islet transplantation. In the
renal subcapsular space, there was robust engraftment of mouse and
human islets. Magniﬁcation 200. B: Frequency of diabetes in mouse
or human islet recipients. No signiﬁcant differences were observed
between recipients of mouse or human islets. Small vertical bars
indicate censored data, i.e., mice that were found dead or were
removed from the study for other analyses. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
TABLE 1
Human HSC engraftment in the spleen of NRG and NRG-Akita
mice
NRG NRG-Akita
n 16 12
Total splenocyte number (10
6) 17.4  4.3 23.1  3.5
Total human leukocytes (%)
CD45
 58.8  6.1 50.98  4.9
B lineage (% of CD45)
CD20
 69.4  2.9 71.2  2.8
T lineage (% of CD45)
CD3
 5.2  1.6 8.6  3.9
CD4
 CD45RA
 5.7  2.6 4.2  1.2
CD4
 CD45RO
 3.3  1.1 4.5  1.4
CD4
 FoxP3
 0.7  0.2 0.8  0.2
CD8
 CD45RA
 4.7  1.7 6.3  2.0
CD8
 CD45RO
 1.2  0.4 1.6  0.6
Dendritic subsets (from murine
CD45

 cells)
(Monocytic) CD11c
 BDCA2

 2.5  0.3 3.6  0.4
(Plasmacytoid) CD123
 BDCA2
 0.5  0.1 0.4  0.1
Monocyte/macrophage (% of CD45)
CD14
 1.3  0.3 2.0  0.4
Newborn NRG and NRG-Akita mice were irradiated with 400 cGY
and injected with T cell–depleted Umbilical cord blood (UCB)
containing 3  10
4 human CD34
 HSCs by intracardiac injection as
described in research design and methods. The percent of various
human cell populations in the spleen was determined by ﬂow
cytometry 12 weeks later. No signiﬁcant differences were observed.
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FIG. 3. Transplantation of human islet allografts into diabetic NRG-
Akita mice engrafted with human HSC. Diabetic NRG-Akita and HSC-
engrafted NRG-Akita mice were transplanted subrenally with 4,000
human IEQ as described in RESEARCH DESIGN AND METHODS. A: Frequency
of diabetes in islet allograft recipients. NRG-Akita vs. HSC-engrafted
NRG-Akita, P  0.03. B: Representative histology and immunochemical
staining patterns are shown. Note the abundance of insulin-positive
cells and the absence of human CD45-positive cells in non–HSC en-
grafted NRG-Akita mice (left panel). Note the presence of fewer
insulin-positive cells and islet graft inﬁltration by human CD45
 cells
in HSC-engrafted NRG-Akita mice that were normoglycemic at the end
of the experiment (middle panel). Note the scarcity of insulin-positive
cells and moderate numbers of human CD45
 cells in HSC-engrafted
NRG Akita mice that were hyperglycemic at the end of the experiment
and had rejected their human islet allografts (right panel). Magniﬁca-
tion 200. huCD45, human CD45 staining; Insulin, insulin staining. (A
high-quality digital representation of this ﬁgure is available in the
online issue.)
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